| Quarter | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| 29 | 185 | 273 | 348 | 400 | 453 | 614 | |
Growth YoY Revenue Growth YoY% | 839.0 | 88.1 | 46.8 | 30.4 | 53.5 | ||
| 20 | 165 | 252 | 323 | 373 | 424 | 584 | |
| 9 | 20 | 21 | 25 | 27 | 30 | 30 | |
OPM OPM% | 31.9 | 10.8 | 7.5 | 7.0 | 6.7 | 6.6 | 4.9 |
| 2 | 3 | 3 | 3 | 3 | 4 | 4 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
Depreciation DepreciationCr | 0 | 1 | 0 | 1 | 1 | 1 | 2 |
PBT PBTCr | 11 | 23 | 23 | 27 | 29 | 33 | 33 |
| 3 | 4 | 4 | 5 | 7 | 7 | 7 | |
| 8 | 19 | 19 | 21 | 22 | 25 | 25 | |
Growth YoY PAT Growth YoY% | 140.6 | 8.2 | 14.9 | 19.5 | 14.2 | ||
NPM NPM% | 26.9 | 10.3 | 6.9 | 5.9 | 5.4 | 5.4 | 4.0 |
| 1.3 | 4.0 | 11.9 | 17.5 | 18.3 | 20.9 | 20.9 |
| Quarter | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| 29 | 185 | 273 | 348 | 400 | 453 | 614 | |
Growth YoY Revenue Growth YoY% | 839.0 | 88.1 | 46.8 | 30.4 | 53.5 | ||
| 20 | 165 | 252 | 323 | 373 | 424 | 584 | |
| 9 | 20 | 21 | 25 | 27 | 30 | 30 | |
OPM OPM% | 31.9 | 10.8 | 7.5 | 7.0 | 6.7 | 6.6 | 4.9 |
| 2 | 3 | 3 | 3 | 3 | 4 | 4 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
Depreciation DepreciationCr | 0 | 1 | 0 | 1 | 1 | 1 | 2 |
PBT PBTCr | 11 | 23 | 23 | 27 | 29 | 33 | 33 |
| 3 | 4 | 4 | 5 | 7 | 7 | 7 | |
| 8 | 19 | 19 | 21 | 22 | 25 | 25 | |
Growth YoY PAT Growth YoY% | 140.6 | 8.2 | 14.9 | 19.5 | 14.2 | ||
NPM NPM% | 26.9 | 10.3 | 6.9 | 5.9 | 5.4 | 5.4 | 4.0 |
| 1.3 | 4.0 | 11.9 | 17.5 | 18.3 | 20.9 | 20.9 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
Revenue RevenueCr | 213 | 620 | 854 | 1,068 |
Growth Revenue Growth% | 191.9 | 37.6 | 42.7 | |
| 185 | 575 | 797 | 1,008 | |
| 28 | 46 | 57 | 60 | |
OPM OPM% | 13.1 | 7.4 | 6.6 | 5.6 |
| 5 | 5 | 7 | 8 | |
Interest Expense Interest ExpenseCr | 0 | 1 | 1 | 2 |
Depreciation DepreciationCr | 1 | 2 | 3 | 3 |
PBT PBTCr | 32 | 47 | 59 | 66 |
| 6 | 9 | 13 | 14 | |
PAT PATCr | 26 | 38 | 46 | 49 |
Growth PAT Growth% | 47.9 | 20.2 | 16.8 | |
NPM NPM% | 12.2 | 6.2 | 5.4 | 4.6 |
| 5.4 | 32.6 | 39.2 | 41.8 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
Revenue RevenueCr | 213 | 620 | 854 | 1,068 |
Growth Revenue Growth% | 191.9 | 37.6 | 42.7 | |
| 185 | 575 | 797 | 1,008 | |
| 28 | 46 | 57 | 60 | |
OPM OPM% | 13.1 | 7.4 | 6.6 | 5.6 |
| 5 | 5 | 7 | 8 | |
Interest Expense Interest ExpenseCr | 0 | 1 | 1 | 2 |
Depreciation DepreciationCr | 1 | 2 | 3 | 3 |
PBT PBTCr | 32 | 47 | 59 | 66 |
| 6 | 9 | 13 | 14 | |
PAT PATCr | 26 | 38 | 46 | 49 |
Growth PAT Growth% | 47.9 | 20.2 | 16.8 | |
NPM NPM% | 12.2 | 6.2 | 5.4 | 4.6 |
| 5.4 | 32.6 | 39.2 | 41.8 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|
Equity Capital Equity CapitalCr | 1 | 6 | 12 | 12 |
Reserves ReservesCr | 85 | 250 | 339 | 524 |
| 149 | 122 | 149 | ||
| 3 | 29 | 42 | ||
| 257 | 433 | 579 | 788 | |
| 210 | 221 | 295 | ||
| 48 | 211 | 284 | ||
| 257 | 433 | 579 | 788 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|
Equity Capital Equity CapitalCr | 1 | 6 | 12 | 12 |
Reserves ReservesCr | 85 | 250 | 339 | 524 |
| 149 | 122 | 149 | ||
| 3 | 29 | 42 | ||
| 257 | 433 | 579 | 788 | |
| 210 | 221 | 295 | ||
| 48 | 211 | 284 | ||
| 257 | 433 | 579 | 788 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| 4 | 7 | 18 | |
| -9 | -11 | -15 | |
| 24 | 6 | 1 | |
Net Cash Flow Net Cash FlowCr | 19 | 3 | 5 |
Free Cash Flow Free Cash FlowCr | 3 | 3 | 4 |
CFO To PAT CFO To PAT% | 13.9 | 18.2 | 39.3 |
CFO To EBITDA CFO To EBITDA% | 12.9 | 15.3 | 32.0 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| 4 | 7 | 18 | |
| -9 | -11 | -15 | |
| 24 | 6 | 1 | |
Net Cash Flow Net Cash FlowCr | 19 | 3 | 5 |
Free Cash Flow Free Cash FlowCr | 3 | 3 | 4 |
CFO To PAT CFO To PAT% | 13.9 | 18.2 | 39.3 |
CFO To EBITDA CFO To EBITDA% | 12.9 | 15.3 | 32.0 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|
Market Cap Market CapitalizationCr | 1,016 | 1,319 | 740 | 963 |
Price To Earnings Price To Earnings | 49.4 | 45.4 | 20.0 | 19.6 |
Price To Sales Price To Sales | 4.8 | 2.1 | 0.9 | 0.9 |
Price To Book Price To Book | 6.4 | 5.2 | 2.1 | 2.7 |
EV To EBITDA EV To EBITDA | 36.0 | 29.2 | 13.3 | 16.4 |
GPM GPM% | 19.4 | 12.7 | 11.8 | 11.8 |
OPM OPM% | 13.1 | 7.4 | 6.6 | 5.6 |
NPM NPM% | 12.2 | 6.2 | 5.4 | 4.6 |
ROCE ROCE% | 32.8 | 17.5 | 16.0 | 12.1 |
ROE ROE% | 29.9 | 15.0 | 13.2 | 9.2 |
ROA ROA% | 10.1 | 8.9 | 8.0 | 6.3 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|
Market Cap Market CapitalizationCr | 1,016 | 1,319 | 740 | 963 |
Price To Earnings Price To Earnings | 49.4 | 45.4 | 20.0 | 19.6 |
Price To Sales Price To Sales | 4.8 | 2.1 | 0.9 | 0.9 |
Price To Book Price To Book | 6.4 | 5.2 | 2.1 | 2.7 |
EV To EBITDA EV To EBITDA | 36.0 | 29.2 | 13.3 | 16.4 |
GPM GPM% | 19.4 | 12.7 | 11.8 | 11.8 |
OPM OPM% | 13.1 | 7.4 | 6.6 | 5.6 |
NPM NPM% | 12.2 | 6.2 | 5.4 | 4.6 |
ROCE ROCE% | 32.8 | 17.5 | 16.0 | 12.1 |
ROE ROE% | 29.9 | 15.0 | 13.2 | 9.2 |
ROA ROA% | 10.1 | 8.9 | 8.0 | 6.3 |
| Market CapitalizationMkt CapCr | 3,724 | 3,302 | 2,059 | 2,058 | 1,569 | 963 | 394 |
| Close PriceClose₹ | 84.16 | 468.95 | 21.90 | 335.95 | 1,110.15 | 817.60 | 893.20 |
| IndustryIndustry | Pharma Others | Pharma Others | Pharma Others | Pharma Others | Pharma Others | Pharma Others | Pharma Others |
| Price To EarningsPE | 82.51 | 9.74 | 21.68 | 111.61 | 5.67 | 19.57 | 11.99 |
| Price To SalesPS | 32.91 | 1.39 | 3.97 | 2.85 | 1.71 | 0.90 | 2.30 |
| RevenueRevenueCr | 113 | 2,369 | 518 | 721 | 918 | 1,068 | 171 |
| Revenue Growth TTMRev Gr TTM% | 222.2% | 6.4% | 0.6% | 19.4% | 11.3% | 42.7% | 7.8% |
| PAT Growth TTMPAT Gr TTM% | 270.5% | 283.1% | 51.6% | 323.7% | 317.3% | 16.8% | -0.4% |
| Market CapitalizationMkt CapCr | 3,724 | 3,302 | 2,059 | 2,058 | 1,569 | 963 | 394 |
| Close PriceClose₹ | 84.16 | 468.95 | 21.90 | 335.95 | 1,110.15 | 817.60 | 893.20 |
| IndustryIndustry | Pharma Others | Pharma Others | Pharma Others | Pharma Others | Pharma Others | Pharma Others | Pharma Others |
| Price To EarningsPE | 82.51 | 9.74 | 21.68 | 111.61 | 5.67 | 19.57 | 11.99 |
| Price To SalesPS | 32.91 | 1.39 | 3.97 | 2.85 | 1.71 | 0.90 | 2.30 |
| RevenueRevenueCr | 113 | 2,369 | 518 | 721 | 918 | 1,068 | 171 |
| Revenue Growth TTMRev Gr TTM% | 222.2% | 6.4% | 0.6% | 19.4% | 11.3% | 42.7% | 7.8% |
| PAT Growth TTMPAT Gr TTM% | 270.5% | 283.1% | 51.6% | 323.7% | 317.3% | 16.8% | -0.4% |